image
Healthcare - Drug Manufacturers - General - NASDAQ - US
$ 124.99
-2.88 %
$ 18.3 B
Market Cap
12.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one BIIB stock under the worst case scenario is HIDDEN Compared to the current market price of 125 USD, Biogen Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one BIIB stock under the base case scenario is HIDDEN Compared to the current market price of 125 USD, Biogen Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one BIIB stock under the best case scenario is HIDDEN Compared to the current market price of 125 USD, Biogen Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BIIB

image
$155.0$155.0$150.0$150.0$145.0$145.0$140.0$140.0$135.0$135.0$130.0$130.0$125.0$125.0$120.0$120.0$115.0$115.0$110.0$110.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
9.68 B REVENUE
-1.62%
2.22 B OPERATING INCOME
5.80%
1.63 B NET INCOME
40.53%
2.88 B OPERATING CASH FLOW
85.85%
-799 M INVESTING CASH FLOW
80.51%
-684 M FINANCING CASH FLOW
-457.80%
2.43 B REVENUE
-0.97%
625 M OPERATING INCOME
38.75%
240 M NET INCOME
-9.82%
259 M OPERATING CASH FLOW
-65.92%
-47.3 M INVESTING CASH FLOW
-154.30%
-23 M FINANCING CASH FLOW
-291.14%
Balance Sheet Biogen Inc.
image
Current Assets 7.46 B
Cash & Short-Term Investments 2.38 B
Receivables 1.87 B
Other Current Assets 3.21 B
Non-Current Assets 20.6 B
Long-Term Investments 227 M
PP&E 3.54 B
Other Non-Current Assets 16.8 B
8.47 %6.66 %11.45 %12.61 %59.99 %Total Assets$28.0b
Current Liabilities 5.53 B
Accounts Payable 424 M
Short-Term Debt 1.75 B
Other Current Liabilities 3.36 B
Non-Current Liabilities 5.8 B
Long-Term Debt 4.88 B
Other Non-Current Liabilities 923 M
3.74 %15.43 %29.61 %43.07 %8.14 %Total Liabilities$11.3b
EFFICIENCY
Earnings Waterfall Biogen Inc.
image
Revenue 9.68 B
Cost Of Revenue 2.31 B
Gross Profit 7.37 B
Operating Expenses 5.15 B
Operating Income 2.22 B
Other Expenses 587 M
Net Income 1.63 B
10b10b9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0010b(2b)7b(5b)2b(587m)2bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
76.12% GROSS MARGIN
76.12%
22.93% OPERATING MARGIN
22.93%
16.87% NET MARGIN
16.87%
9.76% ROE
9.76%
5.82% ROA
5.82%
7.83% ROIC
7.83%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biogen Inc.
image
7b7b6b6b5b5b4b4b3b3b2b2b1b1b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 1.63 B
Depreciation & Amortization 673 M
Capital Expenditures -360 M
Stock-Based Compensation 291 M
Change in Working Capital -155 M
Others 517 M
Free Cash Flow 2.52 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biogen Inc.
image
Wall Street analysts predict an average 1-year price target for BIIB of $221 , with forecasts ranging from a low of $118 to a high of $315 .
BIIB Lowest Price Target Wall Street Target
118 USD -5.59%
BIIB Average Price Target Wall Street Target
221 USD 77.14%
BIIB Highest Price Target Wall Street Target
315 USD 152.02%
Price
Max Price Target
Min Price Target
Average Price Target
350350300300250250200200150150100100Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Biogen Inc.
image
Sold
0-3 MONTHS
781 K USD 2
3-6 MONTHS
1.31 M USD 1
6-9 MONTHS
17.3 K USD 1
9-12 MONTHS
88 K USD 1
Bought
152 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress – Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass. globenewswire.com - 2 weeks ago
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a. businesswire.com - 2 weeks ago
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies. zacks.com - 3 weeks ago
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure. globenewswire.com - 4 weeks ago
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen's applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months. globenewswire.com - 1 month ago
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA® (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy an. businesswire.com - 1 month ago
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once yearly dosing. An interim analysis of the Phase 1 study in participants with SMA who were previously treated with gene therapy was conducted to inform the decision on whether to move salanersen forward into registrational studies. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data shows clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over 1 year. These data will be presented today at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. globenewswire.com - 1 month ago
Biogen: Investors Are Missing The Bigger Picture Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter of 2025. So, the strong demand for Skyclarys and Leqembi helps strengthen Biogen's balance sheet and also allows it to actively rejuvenate its portfolio of product candidates aimed at treating autoimmune diseases. seekingalpha.com - 1 month ago
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to globenewswire.com - 1 month ago
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO. globenewswire.com - 1 month ago
Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) Biogen Inc. (NASDAQ:BIIB ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET Company Participants Robin C. Kramer - Executive VP & CFO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great. seekingalpha.com - 1 month ago
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. globenewswire.com - 1 month ago
8. Profile Summary

Biogen Inc. BIIB

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 18.3 B
Dividend Yield 0.00%
Description Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Contact 225 Binney Street, Cambridge, MA, 02142 https://www.biogen.com
IPO Date Sept. 17, 1991
Employees 7605
Officers Ms. Nicole Murphy Executive Vice President and Head of Pharmaceutical Operations & Technology Mr. Sean Godbout Chief Accounting Officer & Global Corporate Controller Mr. Tim Power M.B.A., Ph.D. Head of Investor Relations Mr. Adam Keeney Ph.D. Executive Vice President & Head of Corporate Development Ms. Robin C. Kramer Executive Vice President & Chief Financial Officer Dr. Priya Singhal M.D., M.P.H. Executive Vice President & Head of Development Mr. Christopher A. Viehbacher President, Chief Executive Officer & Director Ms. Susan H. Alexander Esq. Executive Vice President & Chief Legal Officer Ms. Natacha Gassenbach Chief Communication Officer & Head of Corporate Affairs Dr. Ginger Gregory Ph.D. Executive Vice President & Chief Human Resources Officer